17TH ANNUAL NEUROTRAUMA SOCIETY MEETING

在此申请中，我们请求为将于1999年10月22日和23日在佛罗里达州迈阿密海滩举行的第17届全国神经创伤学会研讨会提供部分资金支持。为了方便不同领域的神经学家出席，会议与神经科学学会第29届年会联合举行。这次会议的计划比往年更大，将有19场特邀讲座和12场从会员提交的摘要中挑选出来的演讲。45%的演讲者将来自神经创伤协会以外的地方。第17届年度研讨会将集中讨论神经创伤研究中的争议和辩论领域，并展示神经科学的新研究领域，丰富的内容可转化为神经创伤领域的研究。这次会议的主题是“神经创伤的当前争议：从替补席到床边。”这次会议的新特点将是关于神经创伤中的细胞因子的Point-Counter Point辩论，以及旨在分析创伤性脑损伤第三阶段临床试验失败的原因的会议，与它们在脊髓损伤中的成功形成对比。应会员的要求，增加了额外的海报展示环节(现在总共6个小时)。会议主题包括：1)线粒体事件介导中枢神经系统损伤后延迟性细胞损伤和死亡；2)体外模型如何帮助我们了解中枢神经系统损伤的病理生物学；3)点对点辩论：细胞因子是脑损伤后继发性脑损伤的介质；4)脊髓损伤后延迟的变性和再生；5)临床试验-为什么它们未能改变创伤性脑损伤的临床实践？

In this application, we request partial funding support for the 17th Annual National Neurotrauma Society Symposium which will be held in Miami Beach, Florida, October 22 and 23, 1999. In order to facilitate attendance of a diverse spectrum of neuroscientists, the meeting is held in conjunction with the society for Neuroscience 29th Annual meeting. The program for this meeting is larger than in previous years, and will feature 19 invited lectures, and 12 presentations selected from abstracts submitted by the membership. 45 percent of the speakers will be from outside the Neurotrauma Society. The 17th Annual Symposium will focus on areas of controversy and debate in Neurotrauma Research as well as presenting new areas of research in Neuroscience, rich for translation into the Neurotrauma arena. The theme for the meeting will be "Current Controversies in Neurotrauma: Bench to Bedside." New features of this meeting will be a Point-Counter Point debate on cytokines in Neurotrauma, and a session designed to analyze reasons for failure for Phase III clinical trials in traumatic brain injury, in contrast to their success in spinal cord injury. Extra poster presentation sessions (now a total of 6 hours) have been added, at the request of the membership. The session topics include: 1) Mitochondrial events mediate delayed cell damage and death after CNS injury; 2) How can in vitro models help us understand the pathobiology of CNS trauma; 3) Point-Counter Point debate: Cytokines as mediators of secondary brain damage after TBI; 4) Delayed degeneration and regeneration following spinal cord injury; 5) Clinical Trials-Why have they failed to change clinical practice in Traumatic Brain Injury?